AstraZeneca: Bronchiolitis Obliterans Syndrome trials

The registry lists 11 Bronchiolitis Obliterans Syndrome studies with AstraZeneca as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 8Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
• Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationCompletedNCT01462942Phase 3Results posted
• Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol FumarateCompletedNCT01078623Phase 2Results posted
• Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01054170Phase 2Results posted
• Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/FormoterolCompletedNCT01023516Phase 2Results posted
• A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With TiotropiumCompletedNCT00949975Phase 2Results posted
• A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00703391Phase 2Results posted
• Aclidinium/Formoterol Fixed Combination Dose Finding StudyCompletedNCT00626522Phase 2Results posted
• A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00500318Phase 3Results posted
• A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT01068184Phase 1
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C InfectionTerminatedNCT00401947Phase 2